CCI-779; Torisel®
162635-04-3
1030.3
C56H87NO16
DMF, DMSO, Ethanol
-20°C
mTOR inhibitor with anti-cancer activity. Temsirolimus is a semisynthetic macrocyclic lactone prepared from rapamycin by selective acylation of the 42-hydroxy group with a protected bis(dihydromethyl)propionic acid, followed by deprotection. It has anti-angiogenic effects which may contribute to the antitumor activity of temsirolimus observed in breast cancer. Temsirolimus shows synergistic in vivo anti-myeloma effects in combination with dexamethasone in a xenograft model.
0.1 lbs
Research or further manufacturing use only, not for food or drug use.
